Enigma Genetics™
The Infrastructure Layer for Human Biological Reversion
Pioneering the world's first self-sovereign genetic identity and epigenetic reversion platform, enabling individuals to own, audit, and optimize their biology over their entire lifespan.
Interactive Pitch Deck
The Category: Biological Identity & Reversion
In 2025–2035, the convergence of DNA sequencing, AI, CRISPR therapeutics, privacy regulation, and longevity science creates a once-in-history opening.
The Biological Reversion Economy
The market Enigma anchors is the intersection of:
Digital Identity
Genomics
Health Data Brokerage
Longevity & Regenerative
$340B+ Total Opportunity
Expanding into a trillion-dollar biological restoration market
Enigma isn't a genomics company or a wellness app — we are the infrastructure that future biology runs on.
The Problem
Genomic data is centralized, exploited, and non-revocable
23andMe's bankruptcy confirmed this: DNA becomes a liquidation asset.
Consumers have no consent, no audit, no control
Once your data leaves the tube, you no longer own yourself.
Epigenetic drift — the primary driver of aging — is unmeasured
The single most important biological variable is not being tracked by any consumer platform.
Reversion requires identity, integrity, and longitudinal data
No system today can securely anchor a lifetime of biological change and simulate reversal.
Enigma solves all four simultaneously.
The Solution: The Living Code Stack
A closed-loop ecosystem for identity, security, consent, and biological restoration.
Cypherglyph™
— Biological Identity TokenPatent PendingMachine-readable optical token encoding static genome, dynamic epigenetic drift (Δβ), audit metadata, and regulatory constraints. Think: Genomic passport + epigenetic chronometer.
GeneVault™
— Encrypted Personal Biology VaultZero-knowledge, post-quantum secure repository for genomic files, epigenetic time series, AI interpretations, and CRISPR readiness templates.
Unifacator™
— Biometric Consent EngineLive, on-device authentication issues expiring, signed consent tokens. Every data release is scoped, logged, and cryptographically irreversible.
SignaChain™
— Immutable Audit LedgerEvery event permanently recorded. A compliance and trust moat that no competitor can fake.
OmniMind™
— AI Reversion EngineAnalyzes drift vectors, reconstructs baseline biology, and simulates reversal pathways. The scientific unlock that transforms data into restoration.
Traction & Validation
Patent-pending architecture
Cypherglyph optical encoding, consent engine, secure biological ledger, reversion simulation pipeline
Market pull from clinics & researchers
Longevity clinics, bioinformatics teams, and regenerative medicine labs in active conversations
500+ waitlist
Growing organically through early thought leadership
Increasing academic alignment
Harvard researchers and top epigeneticists showing interest in baseline → drift → reversion model
Business Model
GeneVault Subscription
80–90% margins
Unifacator SDK Licensing
For hospitals, clinics, biotech, pharma
Research Data Royalties
Users receive 80%, Enigma takes 20%
B2B/Government Integrations
Sovereign health IDs, biological passports
ARR Forecast (3-Year)
Year 1
$3.1M
Year 2
$11.3M
Year 3
$23M
Gross margins: 60% → 70%
The Ask: $2.5M Seed Round
Use of Funds
Milestones
- 10,000 subscribed users
- 10 clinic partners
- 3 pharma pilots
- Reversion Engine v1
- GDPR/HIPAA certification
- Cypherglyph manufacturing line
Contact the Founder
Kenneth J. Clark
Founder & CEO
kclark@enigmagenetics.cloud